Compare · BNGO vs RVTY
BNGO vs RVTY
Side-by-side comparison of Bionano Genomics Inc. (BNGO) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNGO and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $12.29B, about 931.2x BNGO ($13.2M).
- Over the past year, BNGO is down 66.5% and RVTY is up 18.2% - RVTY leads by 84.6 points.
- RVTY has been more active in the news (5 items in the past 4 weeks vs 2 for BNGO).
- RVTY has more recent analyst coverage (20 ratings vs 5 for BNGO).
- Company
- Bionano Genomics Inc.
- Revvity Inc.
- Price
- $1.15-0.86%
- $110.22-1.29%
- Market cap
- $13.2M
- $12.29B
- 1M return
- -0.86%
- +8.84%
- 1Y return
- -66.47%
- +18.16%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 2
- 5
- Recent ratings
- 5
- 20
Bionano Genomics Inc.
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Latest BNGO
- Bionano Genomics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Bionano Announces Hiring of Chief Scientific Officer
- Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption
- Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
- Bionano Genomics Inc. filed SEC Form 8-K: Leadership Update
- GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 24 shares, decreasing direct ownership by 9% to 239 units (SEC Form 4) (for withholding tax)
- CHIEF OPERATING OFFICER Oldakowski Mark covered exercise/tax liability with 27 shares, decreasing direct ownership by 3% to 868 units (SEC Form 4) to satisfy withholding tax
- CHIEF MEDICAL OFFICER Chaubey Alka covered exercise/tax liability with 24 shares, decreasing direct ownership by 4% to 620 units (SEC Form 4) (for withholding tax)
- Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 7 shares, decreasing direct ownership by 3% to 253 units (SEC Form 4) (withholding obligation)
- Bionano Genomics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest RVTY
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026
- Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
- Bernstein resumed coverage on Revvity with a new price target
- SEC Form 11-K filed by Revvity Inc.
- Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
- Vice President and CAO Gonzales Anita covered exercise/tax liability with 33 shares, decreasing direct ownership by 0.45% to 7,286 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)